PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
Abstract
:1. Introduction
2. Methods
3. PARP Inhibitors (PARPi)
4. PARPi Clinical Trials
5. Resistance to PARPi
6. PARPi and Immunotherapy
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Bell, K.J.; Del Mar, C.; Wright, G.; Dickinson, J.; Glasziou, P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int. J. Cancer. 2015, 137, 1749–1757. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Knipper, S.; Pecoraro, A.; Palumbo, C.; Rosiello, G.; Luzzago, S.; Deuker, M.; Tian, Z.; Shariat, S.F.; Saad, F.; Tilki, D.; et al. The effect of age on cancer-specific mortality in patients with prostate cancer: A population-based study across all stages. Cancer Causes Control 2020, 31, 283–290. [Google Scholar] [CrossRef] [PubMed]
- American Cancer Society. Survival Rates for Prostate Cancer [Online]. Available online: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 20 November 2022).
- Dal Maso, L.; Panato, C.; Tavilla, A.; Guzzinati, S.; Serraino, D.; Mallone, S.; Botta, L.; Boussari, O.; Capocaccia, R.; Colonna, M.; et al. Cancer cure for 32 cancer types: Results from the EUROCARE-5 study. Int. J. Epidemiol. 2020, 49, 1517–1525. [Google Scholar] [CrossRef]
- Gorodetska, I.; Kozeretska, I.; Dubrovska, A. BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. J. Cancer 2019, 10, 2109–2127. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mehrgou, A.; Akouchekian, M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med. J. Islam. Repub. Iran 2016, 30, 369. [Google Scholar]
- Dorff, T.B.; O’Neil, B.; Hoffman, K.E.; Lin, D.W.; Loughlin, K.R.; Dall’Era, M. 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol. Oncol. 2021, 39, 521–527. [Google Scholar] [CrossRef] [PubMed]
- Morales, J.; Li, L.; Fattah, F.J.; Dong, Y.; Bey, E.A.; Patel, M.; Gao, J.; Boothman, D.A. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev.™ Eukaryot. Gene Expr. 2014, 24, 15–28. [Google Scholar] [CrossRef] [Green Version]
- Grewal, K.; Grewal, K.; Tabbara, I.A. PARP Inhibitors in Prostate Cancer. Anticancer. Res. 2021, 41, 551–556. [Google Scholar] [CrossRef]
- Murai, J.; Zhang, Y.; Morris, J.; Ji, J.; Takeda, S.; Doroshow, J.H.; Pommier, Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J. Pharmacol. Exp. Ther. 2014, 349, 408–416. [Google Scholar] [CrossRef] [Green Version]
- Abida, W.; Patnaik, A.; Campbell, D.; Shapiro, J.; Bryce, A.H.; McDermott, R.; Sautois, B.; Vogelzang, N.J.; Bambury, R.M.; Voog, E.; et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J. Clin. Oncol. 2020, 38, 3763–3772. [Google Scholar] [CrossRef] [PubMed]
- Abida, W.; Campbell, D.; Patnaik, A.; Sautois, B.; Shapiro, J.; Vogelzang, N.; Bryce, A.; Mcdermott, R.; Ricci, F.; Rowe, J.; et al. ESMO 2019: Preliminary Results from the TRITON2 Study of Rucaparib in Patients with DNA Damage Repair-Deficient mCRPC: Updated Analyses. UroToday.com and 2019 European Society for Medical Oncology Annual Meeting, ESMO 2019 #ESMO19, 27 Sept–1 Oct 2019 in Barcelona, Spain. Available online: https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115264-esmo-2019-preliminary-results-from-the-triton2-study-of-rucaparib-in-patients-with-dna-damage-repair-deficient-mcrpc-updated-analyses.html (accessed on 20 November 2022).
- Hussain, M.; Mateo, J.; Fizazi, K.; Saad, F.; Shore, N.; Sandhu, S.; Chi, K.N.; Sartor, O.; Agarwal, N.; Olmos, D.; et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2020, 383, 2345–2357. [Google Scholar] [CrossRef]
- Shah, S.; Rachmat, R.; Enyioma, S.; Ghose, A.; Revythis, A.; Boussios, S. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations. Int. J. Mol. Sci. 2021, 22, 12628. [Google Scholar] [CrossRef] [PubMed]
- Smith, M.R. ESMO 2019: GALAHAD—A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects, A Pre-Specified Interim Analysis. UroToday.com and 2019 European Society for Medical Oncology Annual Meeting, ESMO 2019 #ESMO19, 27 Sept–1 Oct 2019 in Barcelona, Spain. Available online: https://www.urotoday.com/conference-highlights/esmo-2019/esmo-2019-prostate-cancer/115258-esmo-2019-galaha-a-phase-2-study-of-niraparib-in-patients-with-mcrpc-and-biallelic-dna-repair-gene-defects-a-pre-specified-interim-analysis.html (accessed on 20 November 2022).
- Messina, C.; Cattrini, C.; Soldato, D.; Vallome, G.; Caffo, O.; Castro, E.; Olmos, D.; Boccardo, F.; Zanardi, E. BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. J. Oncol. 2020, 2020, 4986365. [Google Scholar] [CrossRef]
- de Bono, J.S.; Mehra, N.; Scagliotti, G.V.; Castro, E.; Dorff, T.; Stirling, A.; Stenzl, A.; Fleming, M.T.; Higano, C.S.; Saad, F.; et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): An open-label, phase 2 trial. Lancet Oncol. 2021, 22, 1250–1264, Erratum in Lancet Oncol. 2022, 23, e207. Erratum in Lancet Oncol. 2022, 23, e249. [Google Scholar] [CrossRef] [PubMed]
- Nitecki, R.; Melamed, A.; Gockley, A.A.; Floyd, J.; Krause, K.J.; Coleman, R.L.; Matulonis, U.A.; Giordano, S.H.; Lu, K.H.; Rauh-Hain, J.A. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol. Oncol. 2021, 161, 653–659. [Google Scholar] [CrossRef]
- Giudice, E.; Gentile, M.; Salutari, V.; Ricci, C.; Musacchio, L.; Carbone, M.V.; Ghizzoni, V.; Camarda, F.; Tronconi, F.; Nero, C.; et al. PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers 2022, 14, 1420. [Google Scholar] [CrossRef]
- Mweempwa, A.; Wilson, M.K. Mechanisms of resistance to PARP inhibitors—An evolving challenge in oncology. Cancer Drug Resist. 2019, 2, 608–617. [Google Scholar] [CrossRef] [Green Version]
- Noordermeer, S.M.; van Attikum, H. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol. 2019, 29, 820–834. [Google Scholar] [CrossRef] [Green Version]
- Gogola, E.; Duarte, A.A.; de Ruiter, J.R.; Wiegant, W.W.; Schmid, J.A.; de Bruijn, R.; James, D.I.; Llobet, S.G.; Vis, D.J.; Annunziato, S.; et al. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell 2019, 35, 950–952, Erratum in Cancer Cell 2018, 33, 1078–1093.e12. [Google Scholar] [CrossRef] [Green Version]
- Karzai, F.; VanderWeele, D.; Madan, R.A.; Owens, H.; Cordes, L.M.; Hankin, A.; Couvillon, A.; Nichols, E.; Bilusic, M.; Beshiri, M.L.; et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer 2018, 6, 141. [Google Scholar] [CrossRef] [PubMed]
Clinical Trial | Phase | Intervention | Condition/Disease | Recruitment Status | ClinicalTrials.gov Identifier |
---|---|---|---|---|---|
BRCAAway | II | Olaparib | mCRPC and DNA-Repair Defects | Recruiting | NCT03012321 |
COMRADE | I/II | Olaparib + Ra 223 dichloride | mCRPC | Recruiting | NCT03317392 |
GALAHAD | II | Niparib | mCRPC and DNA-Repair Anomalies | Active, not recruiting | NCT02854436 |
IMANOL | II | Olaparib after docetaxel | mCRPC | Completed | NCT03434158 |
LuPARP | I | Olaparib + 177Lu-PSMA in mCRPC | mCRPC | Recruiting | NCT03874884 |
MAGNITUDE | III | Niraparib + Abiraterone Acetate + Prednisone vs. Abiraterone Acetate + Prednisone | mCRPC | Active, not recruiting | NCT03748641 |
NCT02893917 | II | Olaparib + Cediranib vs. Olaparib monotherapy | mCRPC | Active, not recruiting | NCT02893917 |
NCT03263650 | II | Olaparib after Cabazitaxel + Carboplatin | AVPC | Active, not recruiting | NCT03263650 |
NCT03338790 | II | Rucaparib + Nivolumab + Docetaxel or Enzalutamide | mCRPC | Active, not recruiting | NCT03338790 |
NCT03516812 | II | Olaparib + Testosterone | CRPC | Active, not recruiting | NCT03516812 |
NCT03572478 | I/II | Rucaparib + Nivolumab | mCRPC and metastatic Endometrial Cancer | Terminated due to lack of efficacy | NCT03572478 |
NCT03834519 | III | Olaparib + Pemprolizumab vs. Abiraterone Acetate or Enzalutamide | mCRPC | Active, not recruiting | NCT03834519 |
NCT03840200 | I | Rucaparib + Ipatasertib | Advanced prostate, breast, ovarian cancer | Completed | NCT03840200 |
NCT04019327 | I/II | Talazoparib + Temozolamide | Prostate cancer | Recruiting | NCT04019327 |
NCT04824937 | II | Talazoparib + Telaglenastat | mCRPC | Not yet recruiting | NCT04824937 |
NCT04846478 | I | Talazoparib + Tazemetostat | mCRPC | Recruiting | NCT04846478 |
NiraRad | IB | Niraparib + Radium-223 | mCRPC | Completed | NCT03076203 |
PLATI-PARP | II | Rucaparib + Carboplatin + Docetaxel | mCRPC with homologous recombination DNA repair anomalies | Recruiting | NCT03442556 |
ProFOUND | III | Olaparib vs. Enzalutamide or Abiraterone Acetate | mCRPC | Active, not recruiting | NCT02987543 |
PROpel | III | Olaparib + Abiraterone | mCRPC | Active, not recruiting | NCT03732820 |
QUEST | I/II | Niraparib Combination Therapies | mCRPC | Active, not recruiting | NCT03431350 |
RAMP | I | RUCAPARIB + other anticancer agents | mCRPC | Active, not recruiting | NCT04179396 |
TALAPRO-1 | II | Talazoparib | Metastatic Castration Resistant Prostate Cancer and DNA-Repair Anomalies | Active, not recruiting | NCT03148795 |
TALAPRO-2 | III | Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy | mCRPC | Active, not recruiting | NCT03395197 |
TOPARP A | II | Olaparib | Advanced prostate cancer | Unknown | - |
TOPARP B | II | Olaparib | mCRPC and DDR alterations | Unknown | NCT01682772 |
TRAP | II | Olaparib + AZD6738 | mCRPC | Active, not recruiting | NCT03787680 |
TRITON 2 | II | Rucaparib | mCRPC | Completed | NCT02952534 |
TRITON 3 | III | Rucaparib | mCRPC | Active, not recruiting | NCT02975934 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kourampi, I.; Tsetzan, I.-P.; Kappi, P.; Jain, N. PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview. Uro 2023, 3, 40-47. https://doi.org/10.3390/uro3010006
Kourampi I, Tsetzan I-P, Kappi P, Jain N. PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview. Uro. 2023; 3(1):40-47. https://doi.org/10.3390/uro3010006
Chicago/Turabian StyleKourampi, Islam, Ioannis-Panagiotis Tsetzan, Panagiota Kappi, and Nityanand Jain. 2023. "PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview" Uro 3, no. 1: 40-47. https://doi.org/10.3390/uro3010006